JCR Pharmaceuticals Management
Management criteria checks 2/4
JCR Pharmaceuticals' CEO is Shin Ashida, appointed in Jun 2005, has a tenure of 19.58 years. directly owns 0.009% of the company’s shares, worth ¥5.87M. The average tenure of the management team and the board of directors is 6.6 years and 5 years respectively.
Key information
Shin Ashida
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 19.6yrs |
| CEO ownership | 0.009% |
| Management average tenure | 6.6yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00
Dec 22
JCR Pharmaceuticals (TSE:4552) Has Announced A Dividend Of ¥10.00
Dec 08JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00
Sep 06What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You
Sep 04JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Aug 23JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Aug 09Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts
Aug 03JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00
Jul 26JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00
Jul 12JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
May 22JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Mar 18JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Feb 29CEO
Shin Ashida (81 yo)
19.6yrs
Tenure
Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President and Chief Operating Officer of JCR...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 19.6yrs | no data | 0.0085% ¥ 5.9m | |
| Director of Accounting Department & Corporate Strategy Department (Finance) | no data | no data | no data | |
| Sr. Exec. Offi. of Admin. | 8.6yrs | no data | no data | |
| Director of Legal Affairs Department - Administration Division | no data | no data | no data | |
| Director | 4.8yrs | no data | 0.22% ¥ 147.9m | |
| Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div. | 4.3yrs | no data | no data | |
| Executive Vice President | 14.5yrs | no data | no data | |
| Senior Advisor | 13.7yrs | no data | no data | |
| Senior Executive Officer & Director of International Affairs | no data | no data | no data | |
| Senior Managing Executive Officer & Executive Director of Business Development Division | less than a year | no data | 0.0066% ¥ 4.5m | |
| Senior Managing Executive Officer of Research | 6.6yrs | no data | 0.0019% ¥ 1.3m | |
| Managing Executive Officer of Production & Executive Director of Production Division | 3.6yrs | no data | no data |
6.6yrs
Average Tenure
70yo
Average Age
Experienced Management: 4552's management team is seasoned and experienced (6.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 19.6yrs | no data | 0.0085% ¥ 5.9m | |
| Director | no data | no data | 0.22% ¥ 147.9m | |
| Senior Managing Executive Officer of Research | 5yrs | no data | 0.0019% ¥ 1.3m | |
| Director | 3.6yrs | no data | 0.0021% ¥ 1.5m | |
| Director & Managing Executive Officer of Development Division | less than a year | no data | no data | |
| Independent Outside Director | 1.6yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 18.6yrs | no data | 0.010% ¥ 7.2m | |
| Independent Outside Director | 2.6yrs | no data | no data | |
| Independent Outside Director | 6.6yrs | no data | no data | |
| Independent Outside Director | 2.6yrs | no data | no data | |
| Independent Outside Director | 7.6yrs | no data | no data | |
| Independent Outside Director | 6.6yrs | no data | no data |
5.0yrs
Average Tenure
65.5yo
Average Age
Experienced Board: 4552's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 02:17 |
| End of Day Share Price | 2025/01/15 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
JCR Pharmaceuticals Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tatsuyuki Arai | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |